Biosimilars Drug Pricing Magazine 
Pharmaceutical Technology
JULY 23, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up!
pharmaphorum
JUNE 12, 2025
Importantly, this type of insight also supports smarter negotiations around drug pricing. In communities where there is only one pharmacy – or none – there is no competition to drive down prices. By identifying these regions, PBMs can better advocate for fair pricing models that reflect real-world access challenges.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 28, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Market growth will be led by the US, which accounted for over 70% of HS sales in 2024 due to a larger diagnosed population, broader biologic access, and premium pricing.
Pharmaceutical Technology
JULY 1, 2025
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence.
Pharmaceutical Technology
JULY 7, 2025
How will RFK Jr’s American dream for vaccines play out?
Pharmaceutical Technology
JULY 2, 2025
Trikafta, known under the brand name Kaftrio in Europe, is the best-selling cystic fibrosis drug in the world, generating revenue of $11.02bn in 2024. Kaftrio loses patient protection in 2037, at which point biosimilars are set to enter the market. Historically, this erodes the market dominance held by the branded drug.
Pharmaceutical Technology
JULY 4, 2025
Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.
Expert insights. Personalized for you.
Let's personalize your content